Swipe left or click here to continue
PUBLISHER
ADVERTISING SALES
+34 635 77 30 05
SUBMISSIONS & FEEDBACK
info@voicesofleaders.com
Voices of Leaders
We are more than an editorial company. We are a socially-aware company formed by mindful individuals that are actively taking action for the good of the planet. We dedicate our efforts to empower everyone to not only be conscious, but also become proactive in what's happening in everyday life. As a B2B publisher, we inform and connect the voices of prominent leaders in innovation, sustainability, circular economy and impact investing through our exclusive digital magazine and a new B2B connecting feature.
At VoL, we don't just make digital magazines, we make a digital communication experience. Touch, click, slide, connect and discover how exactly a digital media experience should feel like.
VoL ONLINE
www.vol.media
Image Credits: Shutterstock (MO_SES Premium, rommma, frank_peters, mailsonpignata, ziviani, Maha Heang 245789, Avigator Fortuner, O-IAHI, Sunward Art, Alfonso Fernandez, YAO23, patruflo, Krunja, BAIVECTOR, Sayan Puangkham).
Source: (Yi-Chiu Group, Taishin Financial Holdings, SEDA, Evermore Applied Materials, Chaheng Precision, TECO, REXLite, Zylux, Advance Green Biotechnology, Mytrex, Win Semiconductors).
EDITORIAL OFFICES
Plaza Pablo Ruiz Picasso, 1, Impact Hub
28020, Madrid - Spain
VoL eMag TEAM
Co-Founder & Editor: Mayte Mascarell
Co-Founder & CFO: Luca Bugialli
Brand Guardian: Javi Mínguez
Editorial Director: Javier Madero
Journalism: Daiva Sen & Natalia Díaz
Lead Graphic Designer: Jorge Romero
Graphic Designer: Estefanía Martínez
Each page of the Voices of Leaders eMag is interactive and animated . When you see one of these icons, we encourage you to discover and enjoy exploring each item.
Click and go to the content.
A brand new era for made in TAIWAN – 2/2
Double issue edition December 2020 - January 2021
More information
Close
Table of contents
Close
Videos
About this issue
A Budding Regional Pharma Leader
Two mentalities — corporate and sustainable
By Daiva Sen
Your trusted investment partner in the Asia-Pacific region
Smart Music To Our Ears
MIT: The rise of a new brand
Made in Taiwan
A Winning Strategy
The Mineral Oil
Guru of Taiwan
MANUFACTURE FOR THE WORLD
Yi-Chiu Group
CCPG
Zylux
Win Seminconductors
Biggest brands in the world have set up manufacturing facilities in Taiwan
The strength
of Taiwan’s
ICT sector
VoL Editorial
CDIB Capital Group
Energy and Finance
DIGITAL REVOLUTION
R&D and further investigation on how to integrate 4IR technologies.
vol.media
7
For the majority of countries the world over—large and small, from Europe to Asia—COVID-19 has proved to be an unprecedented disaster in all senses. In the United States today, it was announced that one person is dying from COVID-19 a minute, in Europe a second wave of coronavirus is battering healthcare systems, pushing them back into lockdowns, and in China, whilst now things there now seem to returning to a level of normality—China’s global reputation of has been damaged irreparably. On top of the endless loss of human life and continued social impact, the global economy has seen its heaviest dip since The Great Depression, unemployment has rocketed, industries such as tourism have been almost completely paralyzed, and many of the world’s governments find themselves caught been the rock of the plunging economy and the hard place of public health.
In the midst of this widespread devastation, with so many so-called developed nations responding so slowly and inefficiently to the pandemic, Taiwan—a small island nation, which is not even admitted into the WHO due to conflicts with China—has been the number one country in the world for dealing with the pandemic, both in terms of health and economy. ‘Team Taiwan’ as it was labelled domestically, responded with a tight public/private sector spirit of collaboration, which resulted in mass-production of PPE to serve the entire country’s population. Moreover, regulation of prices by the government along with a temporary export ban ensured that domestic availability for all, was ensured before companies could begin to sell abroad. Later on, Taiwanese companies donated to desperate European nations, the effective PPE that they had manufactured, as opposed to the faulty equipment that had earlier been sent to the likes of Spain and the UK by China. The importance of PPE production to Taiwan’s global reputation is illustrated by Sy-Ming Guu, President of Mytrex who explains that “the world knows that our products are of good quality. And then with other PPEs they have put quality at a reasonable price. That’s perfect, especially for people who don’t have a lot of money, they need to have an affordable product; that’s very important. Providing good quality with a reasonable cost are the
key issues that our Taiwanese businessmen can promote and win respect for.
Quality, reputation or respect is not built in one day, it is a constant interaction and response.” And at the moment, this interaction very much favors Taiwanese businesses.
A closure of borders and effective track and trace program proves that Taiwan took the threat of the pandemic a lot more seriously than most countries the world over, and as a result, living in Taiwan in 2020 has been a unique experience, a country seemingly untouched by COVID-19 with life going on as usual. The global economy has of course taken a huge hit, which naturally has affected Taiwan as well, but not nearly as much as it has the majority of the world which has had to impose lockdowns and temporarily paralyze large parts of the economy.
Taiwan is one of only a handful of countries that can describe their COVID-19 response as a hands-down triumph. The result—a huge boost for their global reputation and the MIT (Made In Taiwan) brand. The issue of trust rather than price at a moment of crisis has become apparent. Whilst seeking out the cheapest option (notably in China) may have been the preferred option in the past, paying more for a huge gulf in class is what this pandemic’s legacy may be in terms of manufacture. In our emagazine on Taiwan’s Biotechnology sector we were able to shine a light on how companies ramped up production by 2-3 times, to meet demands that they could never have imagined in the past. In this edition, we will find out the other competitive advantages of Taiwanese manufacture and how they are able to serve both European/US markets and the Chinese market, whilst simultaneously staying out of the trade war’s crossfire.
Business leaders from within Taiwan are all too aware of the possible implications this pandemic may have for the MIT brand, and they are uniformly positive. This is not to say that Taiwanese businesses coldly marked this pandemic as a business opportunity, quite the contrary. As mentioned, the Taiwanese government was quick to regulate the prices of PPE so companies could not take advantage of the desperate need for the equipment, and companies were more than willing to donate material to Europe once they had accelerated their capacities. This altruistic spirit has naturally, also had a highly positive impact on Taiwan’s global image.
Howard Lu-Hao Wu of Evermore Applied Materials tells us that he is grateful for the effectiveness of the Taiwanese government in responding to the pandemic and goes on
High quality medical masks
made in Taiwan.
vol.media
9
to talk through how their actions may turn out to benefit the wider business community in Taiwan, and indeed, what the business world can learn from the public sector. He says the government “sent people to Wuhan and observed very early omens of what was going to happen. The leadership of the government took notice. From a corporate point of view this is something that we can learn, not everyone could notice the early bad news and take really quick action. I think that the teams that went to Wuhan did a good job and observation. This reflects the quality of the management from Taiwan. The manufacturing sector could also leverage such an image.”
COVID-19 is marking a before and after for so many different areas of humanity, and for nations worldwide. Sectors such as health, technology, education are all being reconsidered in different ways following the pandemic.
With the rise of teleworking, daily working lives have evolved. Countries including the United States, South Korea, New Zealand and indeed Taiwan have seen the pandemic become one of the deciding issues, if not the deciding issue in their general elections. The global image of Taiwan and the MIT brand may well be added to the long-list of sectors, countries and aspects of daily life which are marked with a before and
vol.media
9
after stamp in the wake of the pandemic.
Sophia Chiu, Chairman of TECO admits that “MIT was often considered as MIC, people could not tell the difference between China and Taiwan” and goes on to state her belief that “the trends of the image of Taiwan will be a good plus for the MIT products.”
Global business buzz around Taiwan, and in particular, its manufacturing capability looks set to transform it into a regional business leader in the coming years. The talent, efficiency, infrastructure and ambition to achieve this newfound prominence has been in place and grown over the last decade. This process has evidently been accelerated, with the pandemic having diverted the eyes of the world to the country that has best controlled it. Add to that the recent signing of a health, technology and security-focused agreement for increased collaboration with the United States, and it is clear that Taiwan and the MIT brand find themselves on the precipice of a new era of international recognition and cooperation.
Scroll down to keep reading
Energy & Finance
Voices of Leaders: After more than 50 years of experience in the industry, you are known as the “mineral oil guru in Taiwan.” Over that long period of time, has it been difficult for you to adapt to the many changes each decade brings?
Chia-Hong Chin: Yi-Chiu Group started as an industrial oil retailer. Later we became an importing wholesaler, and after a while we made a big decision to have our own production business. Every turn we made was to adapt to some problems and challenges that came along with the development and evolution of our society.
Facing difficulties, I brainstormed for solutions every day. Knowing that only through innovation and transformation, I could turn difficulties to opportunities.
To reduce costs and maximize profits, I invested further in transportation, improved manufacturing equipment, enhanced administrative efficiency, raised employee quality, and perfected financial management. It was about that time I strongly proposed to our government that the market of oil and gas should be privatized. Based on my personal experiences and knowledge about this industry, I believe that only through a free market could we remain competitive in the oil and gas market, which [results] in reduction in cost and flexible options for the people. The government was willing to take my advice, and privatized the market for oil and gas and private gasoline stations on July 16th, 1987. This move eliminated criticisms on CPC Corporation’s monopoly on the oil and gas market, at the same time promoting a healthy and diverse competition in the industry.
Based on this shift, the industry is willing to provide enhanced quality of oil products, with lower prices and additional services.
VoL: What new technologies are Yi-Chiu Group currently implementing in its operations?
CC: Yi-Chiu Group is now actively attending and housing all kinds of activities in the board of trade, encouraging professional managers to pursue further studies in order to understand the dynamic development of the new market and the advancement of technology.
Yi-Chiu is heading toward Industrial 4.0 step by step. Based on integration of data systems we can build Big Data within. Through the effort of standardization and systematization, we can enable the executives to make rapid, informed, and quality decisions. Later we plan to seek for upstream and downstream partners to develop AI in Smart Manufacturing. This process can be called Industrial 3.5. It is a more suitable choice for most SMEs in Taiwan.
VoL: Around the world, sustainability and environmental friendliness is more central to global collective consciousness than ever before. Given the growing demand for more sustainable energy and fuel, does Yi-Chiu Group have any plans to move into renewable energy? What is the potential you see for renewable energies in Taiwan?
CC: In 2014, 4C Offshore generated a report concerning the rank of average wind speed in 23 years, and pointed out that of the top 20 zones of potential around the world, 16 are in the Taiwan Strait. This shows that Taiwan has a great potential to develop offshore wind power.
Sustainable development must be considered in eco-friendly conditions.
Click to read
Mr. Chia-Hong Chin
Chairman of
Yi-Chiu Group
Echoing the governmental policy, Yi-Chiu adapted solar power and installed the solar power generator on the rooftop of the plant. Yi-Chiu also developed plans to recycle and reuse waste materials, including waste glass and waste diapers. Considering the aging population in Taiwan, senior day care services and senior diapers are in great demand. Yi-Chiu is actively investing and developing in recycle-and-reuse technology.
VoL: Taiwan has been identified worldwide as one of the countries that has responded to the coronavirus crisis most effectively. Given the global image Taiwan has given over the last few months, what are the possible implications and benefits for the “Made in Taiwan” brand? How should the country take advantage of its recently strengthened global reputation?
CC: COVID-19 will surely leave an indelible page in the history of the fight against human diseases. God bless Taiwan! This time, we are working together to build up a good reputation for epidemic prevention in Taiwan, such as the experience of building up the mask production line, which resulted in 60 production lines being set up in just 25 days.
This shows that Taiwan’s small and medium-sized manufacturing industries, with their high flexibility and high efficiency, have developed into mature textile, petrochemical and auto-chemical industries. It is flexible and can effectively utilize its niche advantage in production and has a strong ability to respond to changes in market demand. So, how do we market Made in Taiwan (MIT) products based on this? To address this question, I believe that Taiwan has the technology to upgrade its marketing power. At the technical level, the government helps companies accelerate and deepen the deployment of intangibles in the regulatory system as a means to expand their R&D ability for international presence and global industry chain collaboration.
How to strengthen the international image of the MIT brand? This will require further development of a commercial marketing system. In this regard, I have tasked the Manufacturers United General Association of Industrial Park to develop ideas and concepts to use IT technology to create an e-commerce platform for communication between manufacturers and to assist in marketing Taiwan’s small and medium-sized manufacturers to the international market. More importantly, it is to understand international market demands and conditions as a driving force in the upgrading and transformation of Taiwan’s industries.
VoL : What message would you give to those looking to Taiwan as a land of opportunity? Why should businesses and investors look to Taiwan?
CC: Geographically Taiwan is situated in a critical location for strategies and transportation, its politics, technologies, environmental investment, and law and order are of high standard. Our government provides excellent support to assist manufacturers to set up their factories, including the airports and harbors of great land and hydroelectricity, and convenient logistics and freight services for exportation. Our government is also investing greatly in land development for factory sites. Up until June 6, 2020, Taiwan has invested in the three “Invest in Taiwan” plans, a total of $1,193 trillion NTD, and the number of applicants reached 521, creating 84,000 job opportunities. In the “Welcome Back Action Plan,” the government is funding $762 billion NTD to 189 businesses, creating an estimate of 61,984 job opportunities.
As the Chinese government is reinforcing the Hong Kong version of the National Security Law, it seems that the time for “One country, One system” has come, and this law worries many in the field of law, diplomacy, and business. According to some reports, 60% of the members believe that the Hong Kong version of the National Security Law will damage their business operations, because the scope and executions of this law are uncertain, and may violate the right of autonomy in Hong Kong, affecting its judicial independence, and changes its international status. More than half of the members are very worried about the future of Hong Kong, and another 30% are considering transferring their funds and assets out of Hong Kong.
I personally believe that the investment environment in Taiwan is fully supported and protected. In general, Taiwan is politically, economically, publicly safe and steady. The people are passionate, diligent, and active. The Taiwanese value environmental protection as well as economic development. International enterprises such as Google, Microsoft, and Esmer have come to set up factories in Taiwan. I hope we can use this opportunity to market “Ilha Formosa” — “The Beautiful Island” to all corners of the world.
Following the privatization of the Taiwanese oil industry in the late 80s, Yi-Chiu Group emerged as the giants of the mineral oil world in Taiwan. Their Chairman and Founder Chia-Hung Chin has since become known as the mineral oil guru of Taiwan; the group having not just oil, but international trade and environmental protection under the large umbrella of its businesses. That said, in its sixty-year-plus history, now is not the time to rest on laurels. Chia-Hung himself acknowledges that “the amount of natural gas and oil used in the petrochemical industry will slowly decrease.” Looking for solutions to this decrease, Chia-Hung’s approach to challenges does not appear to have changed a great deal. He talks about solutions to the early challenges faced by Yi-Chiu, and how he would “brainstorm for solutions every day, knowing that only through innovation could I turn this difficulty to opportunity.” This idea of innovation as a way of turning difficulty into opportunity, can be seen reflected as Yi-Chiu tries to negotiate the decline of the petrochemical industry that they predict. Branching into sustainable business and renewable energy is gradually being outlined as Yi-Chiu Group’s future. Chia-Hung’s son, Jonathan Chin, the youngest of seven siblings, appears to be the one who is going to manage this future, and is already playing a part in the transition towards it, having steered his father in the direction of sustainability.
Jonathan Chin is far from your average 23-year-old, as he prepares to take on the task of filling the enormous boots of his father, A.K.A Taiwan’s mineral oil guru.
Energy & Finance
Jonathan Chin
General Manager of Yi-Chun Group
Voices of Leaders: Why is it so important for you to remain involved in the family business?
Jonathan Chin: This big legacy is created by my father. And I love my father. I want to think about what he cares about the most. His legacy could be gone in the future, and I do not want to see that. My father needs help with his business. He is a successful businessman but is facing potential danger in the future when there’s no-one to inherit his legacies. I really want to help a loved one to get his problem solved. I think this is the best way to give back to my father.
VoL: A couple of years ago you returned to Taiwan from the United States. Both on a personal level, and as a business leader, what is it about Taiwan that makes you want to continue your business career here?
JC: I have many resources in Taiwan which can help me accelerate to become a businessman. My goal is to help Yi Chiu Group, and Yi Chiu is in Taiwan. I will stay in Taiwan for Yi Chiu Group. I started my own business because I want to help Yi Chiu Group in the future.
VoL: Around the world, sustainability and environmental friendliness is more central to global collective consciousness than ever before. Given the growing demand for more sustainable energy and fuel — do Yi Chiu Group have any plans to move into renewable energy? What is the potential you see for renewable energies in Taiwan?
JC: We are one of the shareholders of Century Wind Power, and the wind farms is what we are doing right now. Our plan to do sustainable energy. The diaper recycling is also a part of sustainable energy, and that is what we are focusing on.
VoL: In your case the idea of making business more sustainable is perhaps more challenging but at the same time more literal, given the nature of petrochemical business. Do you believe this is the greatest responsibility of your generation — making businesses more sustainable?
JC: Since we are a petrochemical business and this business is shrinking, I think we must find other ways of making this business to grow again. So I suggested that my father invest in sustainable companies which could potentially help the company to rise again. It is my and everyone in this company’s responsibility to make it a better place. But when people do not see the problem, they will not have the motivation to change it. I see a threat in the near future and I’m trying my best to stop that problem. I am doing that by starting sustainable business which will be the future trend.
VoL : This issue of sustainability is clearly something that is important to you given that two of the businesses you are looking to launch (Fabu Green Technology and Yi Chun Green Technology) are rooted in this issue. What are the solutions that these two businesses offer?
JC: Fabu Green Technology recycles glass back to light stone, and that light stone is a lighter and stronger material that can be used to build houses, roads and bridges. Also it is a good material to use for farmers to grow plants. You want it to be lighter than water so it can float and sink. These two are making big differences with whatever businesses that use water. It is a light a substitute for stone, concrete, drywall. We provide a safer, stronger and nontoxic or metallic solution.
Click to read
Yi Chun collects used diapers, especially from hospitals and old age homes, then recycles them to raw materials. Diapers take 600 years to fully decompose and are a major environmental threat. Our objective is to recycle the used diapers and turn it back into its original raw material form. Utilizing recycled materials meaning less pollution and less energy consumption. A better and safer future.
VoL : How have you come to be so passionate about sustainability?
JC: I believe sustainability is what will make money in the future. It is the key business of human nature and human beings. The only one thing that can save the planet is sustainability. This is the only business and problem in the future that everyone needs to face. The basic needs for people are food, water, sun, etc. We do not need high technology to survive. The technologies are only for us to live easier, easier for now but harder for tomorrow. Stepping into this business before anyone else will give me the business advantage in the future.
VoL: Taking on four new companies and playing a big role in the family business may well be an intimidating challenge for many people of your age, who have just finished or are still studying, or starting their careers. Do you feel at all daunted by the upcoming challenges or do you feel that you have been preparing for this for a long time?
JC: I have been preparing for this for a long time, ever since I was a child I have known that my father is a businessman and I want to be a businessman in the future, that was my goal and I was raised in this way. Most of my experiences and knowledge came from observing what my father was doing. I did not learn from books and no-one taught me. Years of observation of what my father was doing and thinking why his making the decision has prepared me for who I am.
VoL: What is your personal message of confidence to the international community? Why invest in Taiwan or partner with a Taiwanese company?
JC: Geographical position of Taiwan is in the middle of Asian countries. Our policies are better than that of China. China is not very sustained in treating their businesses. When they are facing environmental or political problems, they can shut down a company instantly. When you are dealing with China, the risks are higher than that of Taiwan. In Taiwan we have many high tech resources such as TSMC and Foxconn.
Mainland China has the advantage of low labor costs, but in the future the labor cost will be gone. It will be AI, IoT or 5G, full-automation. Labor costs will be slim in the future. What’s the substitute for labor? It’s AI technology. Taiwan has a key part for those technologies, so we will develop those for other countries.
In the future when AI is more advanced, the factories will not need any workers, which means where you locate your factory is not that important. Logistics will be a major cost factor. You want your factory near the port so that way your transportation fee is lower. You want your factory to be closer to your customer so the transportation will be lower.
The most important thing is to communicate and to gather information from different countries, different people, so teamwork is their key point, not the technology or the project you’re doing. Labor cost is not important.
Following the privatization of the Taiwanese oil industry in the late 80s, Yi-Chiu Group emerged as the giants of the mineral oil world in Taiwan. Their Chairman and Founder Chia-Hung Chin has since become known as the mineral oil guru of Taiwan; the group having not just oil, but international trade and environmental protection under the large umbrella of its businesses. That said, in its sixty-year-plus history, now is not the time to rest on laurels. Chia-Hung himself acknowledges that “the amount of natural gas and oil used in the petrochemical industry will slowly decrease.” Looking for solutions to this decrease, Chia-Hung’s approach to challenges does not appear to have changed a great deal. He talks about solutions to the early challenges faced by Yi-Chiu, and how he would “brainstorm for solutions every day, knowing that only through innovation could I turn this difficulty to opportunity.” This idea of innovation as a way of turning difficulty into opportunity, can be seen reflected as Yi-Chiu tries to negotiate the decline of the petrochemical industry that they predict. Branching into sustainable business and renewable energy is gradually being outlined as Yi-Chiu Group’s future. Chia-Hung’s son, Jonathan Chin, the youngest of seven siblings, appears to be the one who is going to manage this future, and is already playing a part in the transition towards it, having steered his father in the direction of sustainability.
Jonathan Chin is far from your average 23-year-old, as he prepares to take on the task of filling the enormous boots of his father, A.K.A Taiwan’s mineral oil guru.
Voices of Leaders: Can you give our readers a brief overview of CDIB Capital Group and its core functions?
William Ho: CDIB Capital Group (CDIB) – the first private development-oriented financial institution in Taiwan – was established in 1959. We are an affiliate of China Development Financial (CDF, TWSE:2883), a leading financial institution in the Asia Pacific region.
In its 60 years of history, CDIB has focused on its principal investments and corporate banking activities. We have invested in and provided financial services for domestic and overseas clients in numerous industries, and continue to play a critical role in further developing Taiwan’s private equity and venture capital markets. CDIB has achieved success in its asset management business since its business transformation in 2013. We invest in compelling growth-oriented companies in consumer and retail, value-added manufacturing, and new services, seeking to capitalize on cross-market opportunities in the Asia-Pacific region.
In recent years, we have broadened our investment activities by managing third-party capital from a wide range of sources including high-net-worth individuals, family offices, sovereign wealth funds, pension funds, funds of private-equity funds, insurance companies and banking institutions from around the world. We are committed to ESG (environment, social and governance) practice; just like CDF’s other subsidiaries: China Life, KGI Bank and KGI Securities, we have all signed the “Stewardship Principles for Institutional Investors” enacted by the TWSE.
VoL: How do you see technology and innovation transforming CDIB?
WH: In terms of the capital group, we manage funds focused on technology and also have a growth fund partially focused on technology; as you can see we actually invest a lot in technology. The Group also recently launched the “CDIB Intelligence Partners Fund” which is actively seeking institutional investors in high potential sectors such as technology, targeting global AI-related investment opportunities.
We invest in startups and invite many technology firms in Taiwan as our LPs. We also manage funds for Alibaba to invest in new ventures. In response to the trend of financial innovation, CDIB Capital Group has capitalized on a wealth of investment experience, transformed asset management investment into an industry with great potential.
The Group has thrown its full weight behind supporting local innovation team development in Taiwan, having set up the CDIB Capital Innovation Accelerator to funnel resources into start-ups active in internet & cloud, IoT, mobile internet, and next-generation e-commerce, in order to connect to overseas networks and explore overseas markets. These efforts have recently been recognized with the 2019 Taiwan Corporate Sustainability Awards (TCSA) honors.
VoL: What is your advice to any global executive who is looking at doing business in Asia, especially with the current situation?
Click to read
William Ho
President of CDIB
Capital Group
WH: It depends on the business executive, where the company focus is, what kind of industries and what kind of market it is operating in. To put it in the perspective of private equity (PE), I would definitely focus on Taiwan in the next few years. Local businesses are looking for expansion and partners; some might even sell the majority part or half of the business as the older generation faces succession issues. However, Taiwan is not fully covered by the majority firms, there are plenty of opportunities here and there will be more and more as succession continues to be a really big as well as urgent issue.
In Taiwan, where SMEs play a crucial role to drive economic growth, I see SMEs need more capital and a professional team to help them operate and expand; that is where CDIB can play a major role. We position ourselves as the solution provider, offering financial, management and moreover technology resources. I believe this strategic focus will be a key area for CDIB in the coming years.
We are pleased to announce the successful acquisition of a controlling interest in publicly-listed Jintex Corporation Limited (“Jintex”, TPEX: 1787) in June 2019. The acquisition has been recognized by the Taiwan Mergers & Acquisitions and Private Equity Council (“MAPECT”) and received the “2019 Most Creative M&A Award”. This is especially significant for CDIB as a landmark, take private, control deal in Taiwan’s mid-market space.
VoL: What strategic plans do you have in place for 2020?
WH: We are going to launch more products. We have managed funds denominated in USD, NTD and RMB as well as invested in a range of strategies including mid-market control buying, growth investments, early and later stage venture capital and special situations.
Moreover, CDIB also works on funds in Southeast Asia, Japan, Korea and we also have funds for small companies in the United States. Beyond that, we are focusing on biotech and healthcare, which is going to be a big fund and we are thinking about adding things such as credit and infrastructure as secondary products.
Healthcare is a major issue for us and we have just launched RMB funds for healthcare in China. Essentially, new products related to technology, healthcare, biotech, credit and infrastructure will be launched in 2020.
We recently completed the final round of fundraising for our Global Opportunities Fund with US$136M of committed capital as well as first-round fundraising for the CDIB Yida Private Equity Healthcare Fund with RMB760M of committed capital. In addition, CDIB Intelligence Partners has been launched and this focuses on global AI-related investment opportunities with a targeted fund size of US$75M. Finally, we are also actively raising funds for a second NT dollar-denominated healthcare fund, targeting NT$3B.
VoL: What is your personal message to the international community?
WH: I believe Taiwan will play a major part in the next year or two, especially given the ongoing Sino-U.S. trade issue. In fact, many companies that we have invested in have shown expansion in their businesses; instead of dedicating companies’ resources to China, they chose Taiwan and this has benefitted Taiwan a lot. Taiwan can become much more active in terms of the PE world and more transactions and purchases will be carried out here. In addition, family enterprise succession is going to be a key issue in Taiwan and I hope our scope will grow from there.
CDIB Capital Group has local presence in Hong Kong, Shanghai, Taipei and New York.
For further information, please visit
www.cdibcapitalgroup.com or contact us at
ccapir@cdibh.com.
Energy & Finance
Voices of Leaders: Can you tell our readers about the company and its plans for the future, with a specific focus on key areas such as innovation and technology?
Welch Lin: For the past few years Taishin Holdings has been performing well, with good profitability and a strong and developing franchise across a broad range of financial products and services, including wholesale banking, retail banking, and securities. In Taiwan, the company ranks first in auto loans, third in securities underwriting, fourth in credit cards, and seventh in syndication.
In digital banking, Taishin embraces innovation; it values the user’s experience, continuously improves its systems, and is eager to communicate with the younger generation. In the 2019 “Best FinTech Service Bank” awards held by Global Views Monthly, Taishin won the “Champion” and “Best User-Recommended Service” awards, and received a total of five first prizes in eight categories. In the same year, at the IDC “Digital Transformer Awards,” Taishin won the “Operational Model Master” prize for its efforts to solve cash flow issues by integrating e payment services for retailers through the adoption of a New Payment Service, “pay+.”
In 2015, Taishin began its digital transformation with its digital brand, “Richart,” which injects a new mindset into the banking system, taking particular account of user experience and enabling prompt response capability. In the subsequent years, “Richart” has received several global awards, such as the German Red Dot award for Communication Design, and has maintained a leading market position with 60% market share in Taiwan.
Together with this innovation, Taishin Bank has expanded its ecosystem by engaging in cross industry cooperation on an open banking platform (including Open APIs and Partner APIs), the implementation of which dramatically reduces breakpoints in the service flow while delivering a seamless financial service to customers; the aforementioned “pay+” is one innovation made possible by this platform. Continuing the spirit of collaboration, Taishin has formed a strategic ties with many well-known consumer businesses in Taiwan—from Shin Kong Mitsukoshi Department Store (SKM), to Taipei 101 Mall, and Family Mart convenience stores—to provide comprehensive payment tools, allowing customers to make purchases in member stores using mobile apps. Furthermore, “pay+” makes possible wire transfer services for non-business activities, such as paying rents, sending gifts, splitting a bill, etc.
For the provision of cross-border payments, Taishin has collaborated with the credit card arm of Hana Financial Group, the largest financial conglomerate in South Korea, to launch “Global Loyalty Network (GLN).” In a move that makes Taishin the world’s first GLN Hana cross-border payment member bank, Hana members can, through the use of this platform, make payments when travelling in Taiwan simply by producing their Hana APP codes. The platform also allows Korea’s and Taiwan’s tourists to make on-line currency exchanges, payments, and clearances.
Taishin is the only bank in Taiwan to be simultaneously allied with Alipay, WeChat Pay, and HANA Members; it
Click to read
Welch Lin
President of Taishin
Financial Holdings
will continue expanding its cross-border payment offerings. When designing its innovative functions and convenient services, Taishin embraces these four guidelines in the hope of providing the best customer experience: simplicity, promptness, transparency, and thoughtfulness.
VoL: Can you tell us about Taishin’s commitment to innovation and excellence?
WL: Going forward, Taishin will make every effort to retain its existing market niche and sharpen its competitive edge by adopting new technologies, such as OpenAPI, Big Data, Al, RPA, etc. Taishin considers innovation to be its strongest organizational trait and will therefore adhere to its promise of continual business process reengineering for the goal of providing a better service. So as to lower service costs and improve efficiency and service quality, Taishin designed an in-house employee proposal system which enables staff make suggestions. With the number of proposals this year exceeding 10,000, Taishin’s employees have clearly taken “continual improvement to heart.
Taishin believes strongly in developing a digital mindset within the organization and also of the importance of cultivating digital experts. In order to foster and make best use of its staff’s talents, Taishin created an open office space, has relaxed its dress code, and is proud to work with National Sun Yat-sen University to provide financial innovation master programs—which offer paid internships—as a way of bringing quality staff into the bank’s digital team.
In order to develop comprehensive training courses, strengthen its employees’ digital expertise, and maintain a preparedness for the ongoing digital transformation, Taishin works closely with the IT academic groups at National Taiwan University, FIN & TECH at the Taiwan Academy of Banking and Finance, and the Market Intelligence & Consulting Institute at the Institute for Information Industry. In fact, Taishin is so devoted to the cultivation of talent that it was the proud recipient of one of HR Asia Magazine’s 2018 “Best Companies To Work For In Asia” awards.
VoL: What are the advantages, in your opinion, of investing and doing business in Taiwan?
WL: With a ranking of 19th on the 2018 global GDP list, Taiwan demonstrates a strong and growing soft power. In the WEF 2018 Global Competitiveness Report, Taiwan – along with Germany, the U.S., and Switzerland—was listed as one of the world’s four major “Super Innovators.” With a long-standing position as one of most important high-tech places, Taiwan provides great innovation labs and has attracted investment from many multi-national companies. Last year, Microsoft chose to establish its Al R&D center in Taiwan. IBM has located its IBM Client Center and its IBM Studio here, and adds investment to the island each year. Google set up its data center in Chang Hwa and is establishing its third Asian data center in Tainan.
Energy & Finance
www.taishinholdings.com.tw
Winning customer recognition and society's trust has always been the goal of Taishin Financial Holdings. As a leading Taiwanese financial institution, Taishin recognizes the foundation of success is to maintain consistent and steady growth alongside its customers through its core values of integrity, commitment, innovation and collaboration – principles which help forge lasting client relationships.
Taishin has invested heavily in cutting-edge banking technologies, utilizing AI and big data to provide advanced quality services. Its new ATMs allow customers to get access to cash services via biometric identification. Furthermore, Taishin is the first among its peers to roll out a digital banking service app, called “Richart”, with over 50% of digital banking market share in Taiwan. These innovations qualified Taishin
Taishin Holdings – Your
Smart Partner
Taishin Holdings – Your
Smart Partner
for numerous prestigious awards, including Asia’s Most Intelligent Bank (2019) from the International Data Corporation (IDC) and the Best Retail Bank Taiwan (2019) from The Digital Banker. Welch Lin, President of Taishin Financial Holdings, has said investment in technology is a must which needs to be undertaken for the next generation, while recognizing it may hurt margins in the short term.
Moreover, Taishin is committed to contributing to a sustainable future for all by adhering to the Equator Principles and the implementation of ESG-based policies, with a focus on low-carbon operations and sustainable finance. Such initiatives have seen Taishin rewarded with a place in the Dow Jones Sustainability Index for a second time. “Taishin proudly joins hands with the government, fellow financial institutions,
Taishin Holdings – Your
Smart Partner
and our clients to spur the development of responsible economic, environmental, and social sustainability frameworks,” says Mr. Lin.
Looking ahead, the recruitment and extensive training of top-tier financial professional, as well as the opening of new overseas branches in the Asia-Pacific region will further support Taishin’s ambitions to become a regional player in financial services. “I am very confident in the development of Taishin Holdings,” says Mr. Lin. “In terms of size, we have a very healthy organic growth and we will be more aggressive in the Asia region.”
Scroll down to keep reading
Made in Taiwan
Denry Huang
President of CCSB
Voices of Leaders: What are the most important achievements and developments so far for 2020?
Derek Wang: So far luckily the overall performance of CCPC has grown. It has been stable and we are even experiencing steady growth. The steady growth of CCPC as a group could be dependent and inter-related amongst our affiliated companies. Take for example our core business, human pharmaceuticals, we are very close to the completion of a new manufacturing site down in Tainan, Taiwan. This is a new joint venture project between CCPC and one of our Japanese partners, a pharmaceutical company which specializes in a very special series of brand-name antibiotics. Our partners in Japan will transfer the technology to Taiwan for our joint venture; so in the future the products produced in this manufacturing plant will be exported to Japan and China through our partners’ network. The construction is finished, now it is in the application process for permission from the government. We expect to begin operations in late 2021. This is a very important project we are working on now and are very much looking forward to it.
As for our ongoing contract manufacturing business, namely CDMO and CMO business, with our international partners in the United States, Japan and Europe, actually this year the overall volume of the demand has grown substantially; it is quite good this year, we are pleased with the result. In Taiwan we continue to develop new product lines which require setting up new production lines with new manufacturing technology so we can continue to make the investment domestically for our operations. For the domestic market in Taiwan we continue to leverage the marketing, sales and technology platforms that we have already established in Taiwan and to work with our international partners to bring their brands and products into Taiwan, not just
pharmaceuticals, but also healthcare and consumer products. By bringing in their products using our established platforms in Taiwan, we also enlarge our sales in terms of the healthcare sector in Taiwan.
VoL: Could you share the name of your partners in Japan?
DW: Our new plant is a joint venture project with a mid-sized, very well established Japanese pharmaceutical company. We are manufacturing their very special series of brand-name antibiotics for them. They pretty much dominate the Japanese market in this category. Also they want to work with us to bring their products into the Chinese market.
VoL: With the huge recognition and spotlight that Taiwan has received in 2020, what implications and opportunities do you see for the Made in Taiwan (MIT) brand in the future?
DW: Yes, Taiwan has been highly praised for its highly-effective response to COVID-19. The strength of the national healthcare system in Taiwan is definitely the best defense to combat the pandemic. The Made in Taiwan (MIT) brand should be marketed with pride and should also be carefully selective to be compatible with foreign markets. Take one example, one of our successful products in Taiwan is a popular toothpaste. We have to be careful in selecting the brands to market. For biotechnology and pharmaceuticals, nowadays there are quite a lot of new drugs and even vaccines marketed in the global market which were actually developed in Taiwan and sent to the United States for clinical trials. So Taiwan has the capability and capacity to export these products internationally using the Made in Taiwan (MIT) brand. With the outstanding
Click to read
Derek Wang
Chairman of CCPG
medical researchers and highly-recognized national healthcare system, Taiwan is well positioned at this moment to promote not only public health, but also biotechnology and pharmaceutical industries internationally. The Taiwanese manufacturers and producers are more flexible in adapting quickly to the changing economic conditions internationally. The strategy for promoting Taiwanese products was based on an affordable-price basis has actually served its purpose in terms of establishing Taiwan amongst the industrial nations but now this is the time for Taiwanese manufacturers to be flexible and adopt a new marketing strategy. I believe if we do the right thing and adopt a new market strategy; the next ten years will be even more exciting and profitable than the last ten years.
VoL: Do you see a change from governments or big pharma giants in terms of wanting to get their supply or manufacturing closer to home?
Gloria Hsieh: Yes, I think so. The Taiwanese government took action on calling the local pharmaceutical companies and research institutes to form alliances in order to integrate resources as well as to respond promptly to the country’s needs, in hopes of supplying essential needs locally instead of relying on imported supplies. This is a global trend that has evolved from the COVID-19 pandemic crisis.
VoL: What are Taiwan’s key competitive advantages in pharmaceutical and biotechnology?
DW: The growing biopharma success in Taiwan was partly due to the policies of promotion of the industries put forward by the Taiwanese government. The government does not just understand the sector but has the political capital to make changes for example, institutional support and subsidized tax breaks. Also in this country, doctors and medical professionals are very well respected in this country. More people with medical degrees run for and are elected into political office, so there will be more support on broadening the economy in terms of bringing more bio-presence and Taiwan stands out for its cost-effective and very well-educated workforce. Besides that, there has been a very highly-functioning and competitive infrastructure behind the industries. To operate in a relatively
small-sized market of 23 million people in Taiwan, foreign investment and associations are fundamental to the development of the industries. In Taiwan our outstanding medical and research institutes have been generating enough good research scientists. This is more than enough to attract foreign capital and make the venture a success.
VoL: With all the subsidiaries, affiliates and key projects you have going on, how would you like to see CCPG as a group over the next three years?
WH: We are still a relatively small-sized pharmaceutical enterprise compared to the big pharma and multinational pharma. We would like to develop ourselves into a regional leader, but our scope of operation is still centered on generic pharmaceuticals, so we will continue to work with our affiliated companies on vertical integration. Right now besides the established technology platforms that we already have, we are making investments in new technologies as we continue developing more distinctive formulations in addition to specialized medical devices.
We are also getting involved in different categories of generics, not just the ones that we are working on at the moment. For example, special formulations that act in concert with special medical devices, such as pre-filled syringes, pen injectors, small mist inhalers, etc. These technologies have already successfully been applied to different products that we are also making investments in. Overall, we will explore new opportunities while staying centered in our core capabilities of research and development.
CCPC
CCSB
Voices of Leaders: What are the most important changes and transformations that Wendy International has undergone since its foundation in 1980?
Wendy Lu: After Taiwan became a member of PIC/S, many pharmaceutical factories could not find qualified sources. Wendy holds an enthusiastic heart with sharing and service, trying to assist every pharmaceutical factory to find high-quality raw materials. Furthermore, we assist them to sell products abroad as well.
VoL: Looking to the future, there are of course changes in direction that you yourself will want to implement. We have spoken with several companies where the younger generation is about to take the reins from the previous one, their respective companies having been established already. What do you believe your generation has to offer in leading Taiwanese businesses?
WL: I think Taiwanese companies should see the world with a [longer-term vision] and unite all of us together to sell the good products from Taiwan to the world. Caring for all the people around you, and lighting up the world with love.
VoL: What were the milestones and the company’s performance in the first half of 2020?
WL: Although there was an epidemic issue in the first half of 2020, we always uphold the concept of service first, and quality first. That’s why our sales performance is still rising continuously and steadily. Currently, the main sources of raw materials for supply are from Amri and Gentec, which are from the United States and Europe. And the natural propolis from
B-Natural in Italy. We have an office in China and India now, and are planning to smoothen the communication and review of foreign manufacturers.
VoL: What are the strategic plans in place for 2021?
WL: In the year 2021, Wendy international is going to strengthen the European and American markets, let the sales spread over the world. Our charity association WIL, which means world in love. will be established as well. Wendy wants to assist children in poor countries, giving them better education opportunities. Then back to Taiwan, turn our own country’s future around.
VoL: From which regions are your current international clients? Beyond the countries you already have clients in, do you hope to increasingly expand into markets in North America, Europe, or other parts of Asia?
WL: America, Europe, Asia, Africa, the Middle East, we want to become a global enterprise in the future.
VoL: What is Wendy International’s commitment to R&D and innovation?
WL: Pharmacist Wendy has modulated a pure natural antibacterial essential oil specially for this epidemic, which is deeply loved by many customers at home and abroad. Due to the epidemic situation, many people have to wear masks all day long. Pharmacist Wendy recommends that people can drop a little bit of antibacterial essential oil on tissue, and put it on the inner side of the mask. This would let you
Click to read
Wendy Lu
Managing Director of Wendy International
have double protections and keep a fresh smell all day long.
The pure natural propolis which is selected by our Pharmacist Wendy, has organic certification and process patents. It helps to enhance the immunity of humans and beat the COVID-19 away.
VoL: What has Wendy International’s learned about new technologies over the years? And how has it implemented them?
WL: We not only provide the customers with the raw materials they need, but also assist them in exporting their products. From RD to commercial, we solve all problems and provide a full range of services. After many years, it’s deeply valued by our customers.
VoL: What new technologies is Wendy International currently utilizing or planning to implement in its operations?
WL: Currently, we are committed to RD, as long as the customer provides us the chemical structure, we can help to customize it. In Fine Chemicals, we promote TP3 mainly to manufacture Peptides, VPA is used for color coating, Oxa Acid is used for moisturizing and anti-aging.
We also provide the safest reducing agent in the world, and are helping our customer to do OEM about reduction reaction. Furthermore, we assist customers at home and abroad with OEM and ODM service in PIC/S pharmaceutical factories, skin care and healthy food areas as well.
VoL: Taking into account the global reputation Taiwan has gained from their response to the COVID-19 pandemic, what are the implications and opportunities for the ‘Made in Taiwan’ brand? How should Taiwan take advantage of its recently strengthened global reputation?
WL: During this COVID-19 epidemic, Taiwan has handled it very well, so the situation is still in control. Pharmacist Wendy also specially prepared pure natural antibacterial essential oils, and donated masks and essential oils to abroad, hoping that the earth will soon be healthy again!
VoL: What are Taiwan’s competitive advantages in the pharmaceutical and medical supplies industries?
WL: Currently Wendy is setting up a charity association, hoping to help poor children in various countries get better education and stay healthy. Wendy believes that only education can turn the poverty of a country around. In addition, Wendy likes music and painting very much. There are many good paintings, which will be sold for charity. We welcome all interested people to join in this grand event.
Made in Taiwan
Discover our company, we have been
manufacturing pharmaceuticals since
1980 and since then, we have become
global traders who pride themselves
in offering high quality & certified
pharmaceutical products.
produce
and
provide
Tap the images
to see more!
ACETAMINOPHEN |
Tablet |
120mg |
ACETAMINOPHEN |
Tablet |
300mg |
ACETAMINOPHEN |
Tablet |
500mg |
ACETAMINOPHEN |
Granules |
200mg |
ACETAMINOPHEN |
Syrup |
15mg |
ACETYLCYSTEINE |
Granules |
66.67mg |
ACYCLOVIR |
Cream |
50mg |
ADAPALENE |
Gel |
1mg |
ALLOPURINOL |
Tablet |
300mg |
ALUMINUM DIHYDROXYALLANTOINATE |
Tablet |
100mg |
AMANTADINE HCL |
Capsule |
100mg |
AMBROXOL HYDROCHLORIDE |
Tablet |
30mg |
AMBROXOL HYDROCHLORIDE |
Tablet |
75mg |
AMLODIPINE |
Tablet |
5mg |
AMLODIPINE BESYLATE |
Tablet |
13.86mg |
AMMONIUM CHLORIDE |
S.C Tab. |
300mg |
ANETHOLE TRITHIONE |
S.C Tab. |
12.5mg |
ASPIRIN |
Tablet |
100mg |
ASPIRIN |
EC tab. |
650mg |
ATENOLOL |
F.C.Tab. |
100mg |
ATENOLOL |
F.C.Tab. |
50mg |
AZELAIC ACID |
Cream |
200mg |
AZULENE WATER SOLUBLE |
Tablet |
2mg |
BENZARONE |
Tablet |
100mg |
BENZBROMARONE |
Tablet |
50mg |
BENZOYL PEROXIDE |
Cream |
100mg |
BENZYDAMINE HCL |
F.C.Tab. |
25mg |
BENZYDAMINE HCL |
Solution |
1.5mg |
BETAHISTINE MESYLATE |
Tablet |
12mg |
BETAMETHASONE VALERATE |
Topical liquid |
1.2mg |
BEZAFIBRATE |
F.C.Tab. |
200mg |
BIFONAZOLE |
Cream |
10mg |
BIFONAZOLE |
Solution |
10mg |
BISACODYL |
EC tab. |
5mg |
BISMUTH SUBCARBONATE |
Tablet |
324mg |
BISOPROLOL FUMARATE |
F.C.Tab. |
5mg |
BROMAZEPAM |
Tablet |
3mg |
BROMELAIN |
S.C Tab. |
100mg |
BROMHEXINE HCL |
Tablet |
8mg |
BROMOCRIPTINE MESILATE |
F.C.Tab. |
2.87mg |
BROMPHENIRAMINE MALEATE |
Tablet |
4mg |
CALCITRIOL (DIHYDROXYCHOLECALCIFEROL 1-ALPHA, 25-) |
Soft Cap. |
0.25ug |
CALCITRIOL (DIHYDROXYCHOLECALCIFEROL 1-ALPHA, 25-) |
Soft Cap. |
0.5ug |
CALCIUM CARBONATE |
Tablet |
500mg |
CARBETAPENTANE CITRATE |
F.C.Tab. |
30mg |
CEPHALEXIN |
Granules |
500mg |
CEPHALEXIN |
Cap |
500mg |
CETRAXATE HCL |
Capsule |
200mg |
CHLORDIAZEPOXIDE |
Capsule |
10mg |
CHLORPHENIRAMINE MALEATE |
Tablet |
4mg |
CHLORPROTHIXENE HCL |
Tablet |
50mg |
CHYMOTRYPSIN |
EC tab. |
40mg |
CICLOPIROX OLAMINE |
Cream |
10mg |
CIMETIDINE |
Tablet |
200mg |
CIMETIDINE |
Suspension |
20mg |
CIMETIDINE |
F.C.Tab. |
200mg |
CIMETIDINE |
Tablet |
300mg |
CINNARIZINE |
Tablet |
25mg |
CLEMASTINE |
Tablet |
1mg |
CLOBETASOL PROPIONATE |
Ointment |
0.5mg |
CLOMIPRAMINE HCL |
Capsule |
25mg |
CLONIDINE HCL |
Tablet |
0.15mg |
Clotrimazole |
Tablet |
200mg |
COLCHICINE |
Tablet |
0.5mg |
CYCLOBUTYROL CALCIUM |
Tablet |
110mg |
DANAZOL (CYCLOMEN) |
Capsule |
100mg |
DEXAMETHASONE |
Ointment |
1mg |
DEXAMETHASONE |
Tablet |
0.5mg |
DEXAMETHASONE |
Tablet |
0.75mg |
DEXCHLORPHENIRAMINE MALEATE |
Tablet |
2mg |
DEXTROMETHORPHAN HBR |
Tablet |
20mg |
DEXTROMETHORPHAN HBR |
Tablet |
30mg |
DIAZEPAM |
Tablet |
5mg |
DICLOFENAC SODIUM |
Cap |
50mg |
DICLOFENAC SODIUM |
EC tab. |
25mg |
DICLOFENAC SODIUM |
EC tab. |
50mg |
DICLOFENAC SODIUM |
F.C.Tab. |
100mg |
DICLOFENAC SODIUM |
Supp. |
12.5mg |
DICLOFENAC SODIUM |
Gel |
10mg |
DICLOFENAC SODIUM |
EC tab. |
50mg |
DICYCLOMINE HCL |
Tablet |
10mg |
DIETHYLTOLUAMIDE |
Topical liquid |
500mg |
DIFLUNISAL |
F.C.Tab. |
250mg |
DIMENHYDRINATE |
Tablet |
50mg |
DIMENHYDRINATE |
Solution |
3mg |
DIMETHICONE |
Tablet |
40mg |
DIPHENHYDRAMINE HCL |
Capsule |
50mg |
DIPHENIDOL HYDROCHLORIDE |
Tablet |
25mg |
DIPYRIDAMOLE |
F.C.Tab. |
75mg |
DL-METHYLEPHEDRINE HCL |
Tablet |
25mg |
DOMPERIDONE |
Tablet |
10mg |
EACH CAPSULE CONTAINS : CEFACLOR |
Cap |
250mg |
EBENDAZOLE |
Tablet |
100mg |
ECONAZOLE NITRATE |
Cream |
10mg |
ECONAZOLE NITRATE |
Topical liquid |
10mg |
EPRAZINONE 2HCL |
Tablet |
30mg |
ERYTHROMYCIN |
Ointment |
10mg |
ESTRADIOL |
Cream |
0.6mg |
Estradiol |
Topical liquid |
0.001% |
ESTRADIOL VALERATE |
Tablet |
2mg |
ESTROGEN CONJUGATED |
F.C.Tab. |
0.625mg |
ETHANOL |
Gel |
0.652ml |
ETHANOL |
Spray |
0.736ml |
ETOFENAMATE |
Gel |
100mg |
FENBUFEN |
Tablet |
200mg |
FENOFIBRATE MICRONIZED |
Capsule |
200mg |
FENOTEROL HYDROBROMIDE |
Tablet |
2.5mg |
FERRIC HYDROXIDE POLYMATOSE COMPLEX |
Tablet |
357mg |
FEXOFENADINE HYDROCHLORIDE |
F.C.Tab. |
60mg |
FINASTERIDE |
F.C.Tab. |
5mg |
FLUFENAMATE ALUMINUM |
S.C Tab. |
125mg |
FLUNARIZINE |
Tablet |
5mg |
FLUOCINOLONE ACETONIDE |
Cream |
0.25mg |
FLUOXYMESTERONE |
Capsule |
10mg |
FLURAZEPAM HCL |
Capsule |
30mg |
FLURBIPROFEN |
F.C.Tab. |
100mg |
GENTAMICIN |
Cream |
1mg |
GINKGO BILOBA EXTRACT |
F.C.Tab. |
9.6mg |
GLICLAZIDE |
Tablet |
80mg |
GLICLAZIDE |
Tablet |
30mg |
GLIPIZIDE |
Tablet |
5mg |
GLUCOSAMINE SULFATE CRYSTALLINE |
Cap |
628mg |
GLUCOSAMINE SULFATE CRYSTALLINE |
Capsule |
314mg |
GLYCYRRHIZINIC ACID |
S.C Tab. |
300mg |
GUAIACOL GLYCOLATE |
Tablet |
100mg |
HYDROCORTISONE |
Ointment |
10mg |
HYDROCORTISONE ACETATE |
Ointment |
5mg |
HYDROQUINONE |
Gel |
40mg |
HYDROQUINONE |
Cream |
20mg |
HYDROQUINONE |
Cream |
40mg |
IBUPROFEN |
F.C.Tab. |
200mg |
IBUPROFEN |
F.C.Tab. |
600mg |
IBUPROFEN |
Granules |
200mg |
IBUPROFEN |
Tablet |
600mg |
IBUPROFEN |
F.C.Tab. |
400mg |
IMIPRAMINE HCL |
S.C Tab. |
25mg |
INDOMETHACIN |
Capsule |
25mg |
INDOMETHACIN |
Tablet |
25mg |
INDOMETHACIN |
Topical liquid |
10mg |
IODINE LECITHIN |
S.C Tab. |
5.4mg |
KETOCONAZOLE |
Cream |
20mg |
KETOCONAZOLE |
Topical liquid |
20mg |
KETOTIFEN |
Tablet |
1mg |
LEVONORGESTREL |
Tablet |
1.5mg |
LEVONORGESTREL |
Tablet |
0.75mg |
LEVONORGESTREL |
Tablet |
1.5mg |
Levonorgestrel |
Tablet |
1.5mg |
LIDOCAINE HCL |
Gel |
20mg |
LOPERAMIDE HCL |
Capsule |
2mg |
LOPERAMIDE HCL |
Cap. |
2mg |
LOSARTAN POTASSIUM |
F.C.Tab. |
100mg |
LOSARTAN POTASSIUM |
F.C.Tab. |
50mg |
LOVASTATIN |
Tablet |
20mg |
LYSOZYME CHLORIDE |
Cap. |
20mg |
LYSOZYME CHLORIDE |
Tablet |
50mg |
MEBHYDROLINE NAPHTHALENEDISULFONATE |
Tablet |
76mg |
MECLIZINE HCL |
Tablet |
50mg |
MECOBALAMIN |
Capsule |
0.5mg |
MEDROXYPROGESTERONE ACETATE |
Tablet |
5mg |
MEFENAMIC ACID |
Tablet |
250mg |
MEFENAMIC ACID |
F.C.Tab. |
500mg |
MEPENZOLATE BROMIDE |
Tablet |
25mg |
MEPREDNISONE 21- ACETATE |
Ointment |
2.5mg |
MEQUITAZINE |
Tablet |
5mg |
METFORMIN HCL |
Tablet |
500mg |
METHYLEPHEDRINE DL- HCL |
Tablet |
25mg |
METHYLTESTOSTERONE |
Capsule |
20mg |
METOCLOPRAMIDE HC |
Granules |
10mg |
METOCLOPRAMIDE HCL |
F.C.Tab. |
10mg |
METRONIDAZOLE |
S.C Tab. |
250mg |
MICRONIZED FENOFIBRATE |
F.C.Tab. |
160mg |
MINOCYCLINE (HCL) |
Capsule |
100mg |
MINOXIDIL |
Topical liquid |
20mg |
MINOXIDIL |
Topical liquid |
50mg |
NAFTIFINE HYDROCHLORIDE |
Cream |
10mg |
NALIDIXIC ACID |
Tablet |
500mg |
NAPROXEN |
Tablet |
375mg |
NAPROXEN |
Tablet |
250mg |
NAPROXEN |
Tablet |
100mg |
NICAMETATE CITRATE |
F.C.Tab. |
50mg |
NIFEDIPINE |
Soft Cap. |
10mg |
NITRAZEPAM |
Cap. |
5mg |
NITROXOLINE |
S.C Tab. |
100mg |
NORETHINDRONE ACETATE |
S.C Tab. |
5.705mg |
NOSCAPINE |
Tablet |
20mg |
Nystatin |
Vaginal Tab |
100,000U (potency) |
NYSTATIN |
Capsule |
50MG/UN |
OFLOXACIN |
F.C.Tab. |
200mg |
OFLOXACIN |
F.C.Tab. |
100mg |
OLMESARTAN MEDOXOMIL |
F.C.Tab. |
20mg |
ORLISTAT |
Cap |
120mg |
ORLISTAT |
Cap. |
60mg |
OXAZOLAM |
Capsule |
10mg |
OXETHAZAINE |
Tablet |
10mg |
OXOLAMINE CITRATE |
Tablet |
100mg |
OXYBUTYNIN CHLORIDE |
Tablet |
5mg |
OXYMETAZOLINE HCL |
Topical liquid |
0.5mg |
PANTOPRAZOLE SODIUM SESQUIHYDRAT |
EC tab. |
5.1mg |
PENTOXIFYLLINE |
EC tab. |
100mg |
PHENAZOPYRIDINE HCL |
S.C Tab. |
50mg |
PHENOBARBITAL |
Tablet |
30mg |
PHENOXYBENZAMINE HCL |
Capsule |
10mg |
PHYTOMENADIONE |
Tablet |
5mg |
PIMOZIDE |
Tablet |
4mg |
PIPERILATE HCL |
Tablet |
3mg |
PIPOXOLAN HYDROCHLORIDE |
F.C.Tab. |
10mg |
PIPRINHYDRINATE |
Tablet |
3mg |
PIRACETAM |
Capsule |
400mg |
PIROXICAM |
Capsule |
10mg |
PIROXICAM |
Gel |
10mg |
PIROXICAM |
Cap. |
10mg |
PIROXICAM |
Cream |
5mg |
PODOPHYLLOTOX |
Cream |
1.5mg |
POTASSIUM CRESOLSULFONATE0 |
Liquid |
18mg |
PREDNISOLONE |
Tablet |
5mg |
PROCATEROL HYDROCHLORIDE HEMIHYDRATE |
Solution |
0.005mg |
PROCHLORPERAZINE MALEATE |
Tablet |
8mg |
PROPANTHELINE BROMIDE |
S.C Tab. |
15mg |
PROPRANOLOL HCL |
Tablet |
10mg |
PROPRANOLOL HCL |
Tablet |
40mg |
PSEUDOEPHEDRINE HCL |
Tablet |
60mg |
RETINOIC ACID |
Cream |
0.5mg |
SCOPOLAMINE |
F.C.Tab. |
10mg |
SEAPROSES |
Capsule |
10mg |
SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE |
Capsule |
15mg |
SILYMARIN |
Capsule |
150mg |
SIMVASTATIN |
F.C.Tab. |
40mg |
SIMVASTATIN |
F.C.Tab. |
20mg |
SODIUM FLUORIDE |
Tablet |
2.211mg |
SODIUM FLUORIDE |
Tablet |
0.553mg |
SULFADIAZINE |
Ointment |
50mg |
SULINDAC |
Tablet |
200mg |
TAZAROTENE |
Cream |
1mg |
TEGAFUR |
Cap. |
200mg |
TERBINAFINE HYDROCHLORIDE |
Cream |
10mg |
TERBUTALINE SULFATE |
Tablet |
2.5mg |
TICLOPIDINE HCL |
F.C.Tab. |
100mg |
TINIDAZOLE |
F.C.Tab. |
500mg |
TIPEPIDINE HIBENZATE |
Tablet |
20mg |
TOCOPHEROL NICOTINATE ALPHA DL |
Soft Cap. |
100mg |
TOLNAFTATE |
Ointment |
20mg |
TRANEXAMIC ACID |
Capsule |
250mg |
TRIAMCINOLONE |
Tablet |
4mg |
TRIAMCINOLONE ACETONIDE |
Cream |
1mg |
TRIAMCINOLONE ACETONIDE |
Ointment |
1mg |
TRIAZOLAM |
Tablet |
0.25mg |
TRIMETOQUINOL HCL |
Tablet |
3mg |
ULFADIAZINE SILVER |
Cream |
10mg |
URSODEOXYCHOLIC ACID |
Tablet |
100mg |
URSODEOXYCHOLIC ACID |
Capsule |
300mg |
VERAPAMIL HCL |
F.C.Tab. |
40mg |
VITAMIN U |
S.C Tab. |
25mg |
XYLOMETAZOLINE HCL |
Topical liquid |
1mg |
YDROCHLOROTHIAZIDE |
Tablet |
25mg |
ZINC PYRITHIONE |
Topical liquid |
20mg |
Finished Products
Fine Chemicals and Reagents
API New Item
Essential Oils - Wendy Pharmacist Special modulation
Excipients
API Key Item
API Item
Watch Video
Voices of Leaders: Following your retirement from Academia Sinica, what led you to found ALPS biotech?
Shui-Tien Chen: When I was working in the Academia Sinica, I was passionate about science and I always hoped that the results of science could contribute to society. After I retired from the Academia Sinica, I established ALPS Biotech, the purpose of which is to commercialize the scientific results for public benefit. During my stay at the Academia Sinica, I already had a lot of experience in technology transfer, and I have licensed research results and patents to other biotechnology companies. At the same time, I conducted many years of lung cancer research and found biomarkers of lung cancer. Since lung cancer is the cancer with the highest mortality rate, more than half of the patients in Taiwan are already in clinical stage IV when they are diagnosed. Therefore, we focused on lung cancer as the research subject. As for Antrodia cinnamomea, it is a fungus endemic to Taiwan. Therefore, I have a strong sense of mission in the research on Antrodia cinnamomea. I hope that this important natural resource can benefit the people through ALPS’s research and development in my lifetime. In addition, I also look forward to continuing to train the young generation. Therefore, the establishment of ALPS Biotech is to create an industrial environment so that the young generation can be more able to play to their strengths.
VoL: What are the latest developments related to your lung cancer research?
SC: Through proteomics technology, we found a biomarker in the urine of lung cancer patients, which can be developed into an in vitro diagnosis, and this biomarker also has a high potential for development into immunotherapy. In addition, we have also started many
projects related to natural products. Based on the experience of many patients, we know that Antrodia cinnamomea is a great help for the recovery of cancer patients after surgery. Antrodia cinnamomea also has some effects on the prevention and treatment of COVID-19. At present, we are also actively developing some food additives, and plan to develop food preservation antibacterial ingredients derived from natural herbal extracts. In addition, we are also developing processes for some high profit margin functional food materials, with efforts focused on scale-up and quality control for mass production.
VoL: The Taiwanese government has identified biotechnology as one of the 5+2 industrial clusters. How do you assess the government’s support over the last four years and how easy or difficult it is for a researcher like yourself to set up a company?
SC: The development period of a new drug is very long and requires a lot of resources. It is very difficult for a new company. Therefore, we are very grateful for the government’s support through the investment program of the National Development Fund and the San Fu Global Fund. Relative investment has given ALPS Biotech a very important capital injection, allowing us to continue to invest our enthusiasm in the research and development of technology and new drugs.
VoL: Are the regulations changing at the right speed?
SC: Taiwan has already become a global leader in the semiconductor industry. The government hopes to foster the biotechnology industry to become the next main force in the country. Therefore, the
Click to read
Shui-Tien Chen
PhD, President of
ALPS Biotech
adjustment of laws and regulations is carried out in accordance with this strategic direction. At present, Taiwan’s biotechnology has begun to flourish, with more than 1,000 biotechnology companies participating in the annual biotechnology exhibition. In addition, regulations including manufacturing quality certification have also been in line with international standards, in compliance with US FDA GMP and PIC/S-GMP. The clinical trial regulations in Taiwan are also in-line with international GCP guidelines. The Government has also been giving tax incentives to encourage the development of the biotechnology industry in Taiwan besides assisting new drug developers in complying with international clinical regulations. We hope that the speed of regulatory adjustment can keep up with the speed of development of the biotechnology industry.
VoL: How do you assess the new generation of scientists and researchers who are looking to establish their own company and products?
SC: Entrepreneurship is always a very hard way. Even though I am getting older now, I still encourage the younger generation to actively face challenges. The biotechnology industry requires cooperation and cross-field integration, so the teamwork spirit is a necessary corporate culture. ALPS Biotech is the first batch of companies to be successfully approved to enter the National Biotechnology Research Park. It is committed to creating an environment where many manufacturers and R&D units can interact and cooperate. It is a brand-new biotechnology incubation base in Taiwan. ALPS Biotech can be a starter used as a company that introduces young people into the biotech industry, accumulates experience, and learns to cooperate.
VoL: Where do you see Taiwan’s biggest potential in the global biotech market?
SC: Taiwan has a very strong research momentum, spares no effort in the training of high-level talents, and attaches great importance to intellectual property rights. The transparency of the accounting and financial system is synchronized with the international. Taiwan has been a global leader in the IT, semiconductor, and precision machinery industries recently. Taiwan’s biotechnology can combine these advantages in the future. For example, precision medical materials, telemedicine, integrated AI, and other related industries will be our niche. In addition, Taiwan’s medical standards are ranked third in the world in international assessments, and Taiwan’s national health insurance system and service quality are ranked first in the world.
These advantages are Taiwan’s most important competitiveness in entering the global biotech market.
VoL: What is your personal message of confidence to global executives? How can they rely on Taiwan’s pharmaceutical and biotech industries for their global operations?
SC: Taiwan’s capabilities in biotechnology and pharmaceuticals, especially APIs (active pharmaceutical ingredients). All the API manufacturers in Taiwan have to pass PIC/S GMP inspection by the TFDA. Many of these API companies comply well with international GMP standards and successfully passed US-FDA inspections. Taiwan’s GCP is also performing very well and is very suitable for the clinical trial environment of new drugs. It provides relevant information on Asian races, combines the big data of the health insurance database, integrates medical informatics, and precision medical technology, AI medical treatment, and IT industry, and the development of telemedicine. These are all important resources that global executives should value. In addition, Taiwan’s friendly social environment, political democratization, complete concept of personal information privacy protection, and emphasis on intellectual property rights are all important indicators worthy of global investment.
VoL: With all the projects you have going on at ALPS Biotech and its sister companies, how do you see the group in the next few years?
SC: Sound corporate governance is our primary goal. In the future, we will continue to carry out research on lung cancer, not only to develop in vitro diagnosis, but also to develop immunotherapy and related vaccines. In addition, in many research and development projects of natural products, we also have a great willingness to cooperate with other international biotechnology and pharmaceutical companies, mutual authorization, and joint ventures — including the development of Antrodia cinnamomea botanical new drugs, the extraction and identification of other more biological functional natural substances, the strengthening of more refined and pure processes, the development of faster synthesis techniques, and so on. The goal is that we hope to upgrade ALPS from a biotechnology company to a global pharmaceutical company.
Made in Taiwan
SEDA Chemical Products CO., LTD was established in 1971. SEDA has been running the brand “IMAGER-37” for selling home bedding and medical care products for 20 years, and products including home bedding, medical mattress (anti-pressure injuries), and smart-care mattress/system, smart home bedding. The main material of products is the exclusive memory foam with Visco-Elastic, Open-Cell, and Temperature-Sensitive characteristics, so it can perfectly contour the body shape by differentiating between the body and room temperature. It also offers the maximum contact area for body support and pressure relief (even the fingerprints can be clearly contoured). Products have been awarded Taiwan Excellence Awards, Symbol of National Quality Awards, and TFDA medical device licenses.
In recent years, SEDA has successfully entered the field of medical biotechnology and developed medical care products and smart bedding products. These products have been widely used in Taiwanese hospitals for care and smart living. By developing core materials and technologies, IMAGER-37 aims to become a leading global brand that is synonymous with Smart Sleep, Smart Home, and Smart Care.
Scroll down to discover
Awards & Certifications: Taiwan Excellence Awards, Symbol of National Quality Award of Taiwan, ISO 9001/13485, RoHS and CE.
Made in Taiwan
Voices of Leaders: Since its foundation in 1971, what are the most important changes and transformations that SEDA has undergone?
Wei-Kuan Wang: From 1971 until now, SEDA has kept developing innovative foam materials and products for enhancing people’s life and society’s welfare.
Being a foam maker with a long history, we have been accumulating abundant core technologies and practical experience. The developed key materials are from high resilience foam, integrated skin foam, viscoelastic memory foam and phase change material integrated into foam. The developed products include seats for vehicles and bicycles, office chairs and home sofas, pillows, mattress, cushions for sleep, medical care and rehabilitation products, and smart sensing and IoT mattresses.
The most important change is that we keep adding value to the products using technological innovations for the necessary demand, and the main business model in Taiwan has changed from OEM to ODM and OBM.
VoL: What are the strategic plans in place for 2021?
WW: In order to enhance the competitive power and business development of the company, we have targets to do as following:
1. Keep developing and deepening self-brand business by widely promoting sleep health perspectives and launching new products for good sleep.
2. Extending the market share of medical care products in Taiwan by promoting the importance of preventing pressure injuries
and practically visiting hospitals and nursing homes.
3. Extending the market share of the smart mattress in Taiwan by cooperating with the well-known system integrators for building large scale pilot fields of smart home and smart care applications.
4. Continue developing high value-adding products for pet care products, human lifestyle products, and high flame-retardant products.
5. Aggressively seeking opportunities and partners for OEM, ODM, and OBM business development in global markets, especially the US, European and Japanese markets.
VoL: What is SEDA’s commitment to R&D and innovation?
WW: For sustainable enterprise development, SEDA aims to develop high-quality foam products for better sleep quality and life welfare. And, from the implementation of automatic manufacturing processes and facilities to the developed products’ functions and applications, SEDA keeps insisting on innovating and progressing at all. Besides, we will focus on developing medical care products, and sensing, IoT, and AI bedding products for achieving the demands of the aging society and lack of manpower.
VoL: What has SEDA learned about and how has it implemented new technologies over the years?
WW: Because sleep disorder and aging care are serious global problems, many technologies and products are being developed to solve the rapidly increased demands. As a foam product manufacturer,
Click to read
Wei-Kuan Wang
Chairman of SEDA
SEDA uses exclusive viscoelastic and temperature-sensitive memory foam as the basement to design pressure redistribution for medical care products, and integrate the Phase Change Material for solving the heat (sultry) problem, and integrate Sensing, IoT, and AI technologies for more efficient sleep and telecare service.
VoL: What new technologies is SEDA currently utilizing or planning to implement in its operations?
WW: In routine manufacturing, we have utilized the robotic pouring system for the well-control of foam material, the automatic transportation system for increasing the working efficiency, and RIFD system for better stock management. All the manufacturing processes have passed the ISO international standard. Additionally, there are three main special technologies for developing advanced products:
1. High-density molding memory foam with viscoelastic, temperature-sensitive and open cells. The density is higher than normal foam, so the exclusive memory foam could provide excellent body immersion and envelopment for better pressure redistribution and body support. The key material could be used to design high-end home sleep and medical care products.
2. For solving the heat problem in pillows or mattresses, the present common solution is to use a cooler fabric atop the items, but the cooling time of body impressions is very short. Hence, the phase change material embedding in the high airflow foam is an innovative invention, and the items with PCM can absorb the heat from human and discharge to the outside (with air-conditioned environment) so that the sleep temperature will be controlled well for the long period (at least 8 hours).
3. A smart mattress could facilitate sleep monitoring (body movement, sleep status, and breathing). By integrating deep learning mechanisms, IoT technologies, and ICT platforms, it could facilitate sleep quality management and also be easily connected with the local sleep environment and remote caregiver for better health and safety management.
VoL: Taking into account the global reputation Taiwan has gained from their response to the COVID-19 pandemic, what are the implications and opportunities for the ‘Made in Taiwan’ brand particularly for the pharmaceutical, biotechnology and medical innovation industries? How should Taiwan take advantage of its recently strengthened global reputation?
WW: Taiwan has developed many valuable life experiences, medical resources, and ICT technologies in years. Most of Taiwan’s enterprises have high potential in R&D, and also insist on high-quality product development, so “Made in Taiwan” products are always a well-trusted option, especially the pharmaceutical, biotechnology and medical products which require high accuracy and quality.
Since China’s manpower cost is not an advantage anymore, Taiwanese industries with abundant various resources should be aggressive to connect global business networks, and try to show Taiwan’s technologies innovation and product quality to bring global business possibilities. We strongly believe Taiwan’s brand could be more acceptable in global markets in the coming years.
VoL: What is your message of confidence to global investors and companies that are looking to invest in a Taiwanese company or pursue a joint-venture with a Taiwanese company?
WW: SEDA started in 1971 as a professional PU foam manufacturer in Taiwan and aims to develop high-quality products for sleep health and medical care. SEDA has also run a self-brand “IMAGER-37” in selling home bedding products in department stores in Taiwan for 20 years. Therefore, SEDA has accumulated abundant key technologies and experience, and the related series products have awarded the Taiwan excellence awards and symbol of national quality awards of Taiwan, so SEDA is very confident to provide excellent foam products for users. In the meantime, all of our products comply with international quality standards and are also greatly appreciated in a variety of different markets throughout the world.
If you are interested in any of our products or applications, please feel free to contact us. We are very welcome to cooperate with global partners to form successful business relationships by the OEM, ODM, or OBM business model.
Made in Taiwan